Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 9  Issue 2
Resumption of intracellular Ca2+ cycling as a therapeutic strategy for heart failure
Hiroshi Satoh, Hideharu Hayashi
Pages: 29 - 41
Number of pages: 13
Current Topics in Pharmacology
Volume 9  Issue 2

Copyright © 2005 Research Trends. All rights reserved


Altered cellular Ca2+ handling plays a key role in the pathophysiology of heart failure. A typical aspect of failing heart cells is a decrease in the ability to load Ca2+ in SR, which results in a decreased amplitude and a slowed decay rate of Ca2+ transients, and an increased diastolic [Ca2+]i. This unloaded SR Ca2+ could be ascribed to a decrease in Ca2+ re-uptake by SR Ca2+ ATPase (SERCA), an increase in Ca2+ extrusion by the over-expression of Na+/Ca2+ exchange (NCX), and an increase in the SR Ca2+ leak by the dissociation of FK506-binding proteins (FKBPs) from the SR Ca2+ release channel (ryanodine receptors; RyRs). Many inotropic agents including digitalis and ß-receptor agonists have failed to improve long-term prognosis of heart failure in clinical studies. This review introduces newly developed drugs and gene therapies that target SERCA, NCX and RyRs as a possible therapeutic strategy in heart failure. For the SR Ca2+ uptake, drugs that enhance SR Ca2+ uptake in a cAMP-independent manner, including protein phosphatase inhibitors and MCC-135, are candidates. The SERCA expression and the ablation of phospholamban by gene transfer are also considered. For NCX, the novel specific inhibitors, KB-R7943, SEA0400, and SN-6, and the expression of NCX inhibiting peptide (XIP) would be effective by altering Ca2+ flux from the extrusion to outside the cell to the re-uptake to the SR. For RyRs, JTV519 and the over-expression of FKBP12.6 are expected to increase the binding of FKBP12.6 to RyRs hyper-phosphorylated by protein kinase A, and to reduce the SR Ca2+ leak. Despite limitations for clinical use, the combination of these agents may restore cellular Ca2+ cycling and improve cardiac function with less toxicity.

Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms